Focal cryoablation can kill malignant prostate tissue without affecting the urinary system or a man’s sexual potency, according to a study presented at the Society of Interventional Radiology meeting.
Focal cryoablation can kill malignant prostate tissue without affecting the urinary system or a man's sexual potency, according to a study presented at the Society of Interventional Radiology meeting.
Surgery and radiotherapy have shown effectiveness in combating prostate cancer. They treat the whole gland, however, potentially leading to sexual dysfunction and urinary incontinence.
Focal cryoablation, also known as the "male lumpectomy," targets and destroys only malignant tissue, while preserving healthy tissue in and around the prostate, said principal investigator Dr. Gary Onik, director of surgical imaging at the Center for Surgical Advancement at Florida Hospital in Celebration.
Early findings show that focal cryoablation outclasses standard treatment strategies for cancer control, while reducing the risk of complications. Most prostate cancer patients are potential candidates for the procedure, unlike brachytherapy, which is largely confined to low-risk individuals, Onik said.
To date, Onik and colleagues have treated 60 patients using the technique. Preliminary results for 42 patients who have been followed during eight years show that 95% have had stable prostate-specific antigen tests, with no sign of recurrence. Of 32 patients who were potent prior to the procedure, 78% (25) remain potent versus the average 30% with surgery and 50% with radiation therapy. There are no reports of urinary incontinence postcryoablation.
For many patients, incontinence bears far more importance than impotence. Cryoablation can limit this and other complications without compromising cancer control. If long-term studies confirm these findings, the technique has the potential to change the treatment paradigm, Onik said.
For more information from the Diagnostic Imaging archives:
Real-time MR guides liver cryotherapy
Multiple strategies take aim at removing breast lesions
Imaging aims to improve therapeutic balance
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.